It's about the new oral antidiabetic medications, the ones acting through the incretin pathway like the DPP-4 Inhibitors and GLP-1 analogues and the ones acting on the kidneys like the SGLT-2 inhibitors. Some are used as first line in people more common medications like metformin are not recommended or as second or third line agents. Their pharmacology and advantages over the older medications are looked into.